SCHEMBL3483889

SCHEMBL3483889

O=C(C=Cc1ccc(O)cc1O)c1cccc(NS(=O)(=O)c2ccc(O)cc2)c1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.63
TYR P14679 2/20 0.57
POLB P06746 1/20 0.49
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PTPN1 P18031 1/20 0.48
HSD17B2 P37059 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483887 1.00 CHRNA7 (0.63) CHRNA7TYRPOLBKMT2AKDM4E
SCHEMBL3483606 0.92 CHRNA7 (0.65) CHRNA7TYRKMT2APTPN1HSD17B2
SCHEMBL3483605 0.92 CHRNA7 (0.65) CHRNA7TYRKMT2APTPN1HSD17B2
SCHEMBL3483841 0.91 CHRNA7 (0.50) CHRNA7POLBKMT2AKDM4EMEN1
SCHEMBL3483842 0.91 CHRNA7 (0.50) CHRNA7POLBKMT2AKDM4EMEN1
SCHEMBL3483733 0.91 CHRNA7 (0.50) CHRNA7TYRPOLBKMT2AKDM4E
SCHEMBL3483735 0.91 CHRNA7 (0.50) CHRNA7TYRPOLBKMT2AKDM4E
SCHEMBL3484428 0.88 BACE1 (0.50) CHRNA7POLBKMT2AKDM4EMEN1
SCHEMBL3484431 0.88 BACE1 (0.50) CHRNA7POLBKMT2AKDM4EMEN1
SCHEMBL27840726 0.87 TYR (0.62) CHRNA7TYRKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US disclosed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP disclosed
US-8445722-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2013-05-21 US disclosed
EP-2099440-B1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 SEOUL NAT UNIV IND FOUNDATION (KR) 2013-02-27 EP disclosed
US-20120282619-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY 2012-11-08 US disclosed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 CHRNA7 4573/4885TYR 3484/4885POLB 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.